Member Info for bigAl67

Followed by 0 • Following 0

Followers

bigAl67 is not currently being followed by anyone

Following

bigAl67 is not currently following anyone

Posts (Last 30 Days)

Posts (All Time)

2,761

Last Post

18th Jun 2026

Member Since

1st Jul 2020

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)

10 Jun 2026 - Added Genedrive (GDR) to Timeline

Hi Eureka - Clarification – evidence that you did not Lie, as incognito wants readers to believe -

15th May 2023 at 15:59, Eureka posted:-

‘’ I had a fruitful discussion with the Company earlier today and came away feeling reasonably cheerful. Certainly a number of issues upon which I had questions were clarified. ‘’

‘’ I'm pleased to say that there WILL BE an announcement on the day that the public consultation begins, ie in two days time.’’ - (This i.e. in two days time was Eureka’s belief because it had been publicised that the consultation would start on the 17th May 2023). We know however that Nice later announced that the start date had moved out by two days to the 19th May).

Eureka clarified– ‘’No, Guy, my contact said that there would be an announcement on the day the public consultation began. As I said previously, it was MY assumption that this would be on the previously scheduled date and my apologies to all for that. I suppose a lesson that one must take nothing for granted!’’

- Eureka had been told by a GDR spokesperson that there WILL BE an announcement on the day that the public consultation begins – AND this is exactly what happened – On the day the NICE consultation period started, an RNS was released:- 19 May 2023 07:00 RNS Number : 9399Z – a Quote from this RNS: -

‘‘NICE's final guidance will follow the public consultation period which opens today, 19 May, and is scheduled to close on 9 June 2023’’

The NICE public consultation period had been publicised to start on the 17th May 2023 - no one knew that NICE would put back the start of the public consultation by 2 days – i.e. until the 19th May 2023.

However, That Guy_incognito posted - ‘’I’d take what eureka said with a huge pinch of salt , another poster claimed before they knew someone high up at GDR that confirmed large PoC sales and we all know how that turned out’’ – Posted at 06:44 on the 16th May.

incognito then posted – Eureka – ‘’Where is this GUARANTEED rns’’ – posted at 07:11 on the 17th May 2023

incognito then posted again 5 minutes later – Re Eureka – ‘’What makes this funnier is he (Eureka) called me a liar about something then wouldn’t tell me what, then gets caught fibbing about his inside contacts at gdr’’ – posted at 07:16 on the 17th May 2023

incognito then posted again - Re Eureka

Testing could help prevent further strokes in people with gene variant

People who have had an ischaemic stroke or transient ischaemic attack (TIA) should have a genetic test to find out whether they can be treated with a drug which reduces the risk of further strokes, NICE has said.

19 May 2023

New draft guidance from NICE published today (Friday, 19 May 2023) has recommended clinicians offer laboratory-based genotype testing to people if treatment with the drug clopidogrel is being considered.

NICE currently recommends clopidogrel can be used as an option for treating people at risk of a secondary stroke but this treatment is not suitable for those with certain variations in a gene called CYP2C19 because they cannot convert the drug to the active form.

The genotype test would be used to find out who has these variants so they can be treated with an alternative drug.

If laboratory testing – estimated to cost around £139 per test – is not possible, NICE has said the Genomadix Cube point-of-care test – at a cost of £197 a test – can be used instead.

There are around 100,000 strokes every year in the UK, of which around 43,000 are recurrent strokes. Each year, 46,000 people in the UK have a TIA for the first time – a warning that they are at risk of stroke.

At present no testing takes place to find out who is suitable for treatment with clopidogrel. An estimated 32% of people in the UK have at least one of the highlighted CYP2C19 gene variants. They are more commonly found in people with an Asian family background but can be found in people of any ethnicity. Evidence has suggested that people with these variants have around a 46% increased risk of another stroke when taking clopidogrel compared to those without them.

If the test discovers they have one of the CYP2C19 gene variants, the person will be treated with another medicine, which will be more effective at preventing future blood clots.

Around 11 million items of clopidogrel are dispensed each year at a cost of around £16 million to the NHS.

Mark Chapman, interim director of medical technology and digital evaluation, at NICE, said: “The recommendation is a step forward in ensuring people who have had a stroke receive personalised care thanks to a genetic test run after their DNA is sequenced using their blood or saliva.

“Treatment with clopidogrel is effective in preventing further strokes for the majority of people who don’t have the gene variant. But until now doctors have not known who cannot be treated with clopidogrel until after they’ve had a second stroke or TIA and that could be too late.

“If the CYP2C19 variants are found, other treatment options can be used. This test ensures we’re getting the best care to people quickly, while at the same time ensuring value for money for the taxpayer.”

A consultation has begun on the draft recommendations and consultees can have their say via nice.org.uk until Wednesday, 8 June 2023.

Latest Share Chat

Member Info for bigAl67

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending